Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices

por Chen, Clara, Ravelo, Arliene, Yu, Elaine, Dhanda, Rahul, Schnadig, Ian
Publicado 2015

Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations

por Rapoport, Bernardo Leon, Aapro, Matti, Chasen, Martin R, Jordan, Karin, Navari, Rudolph M, Schnadig, Ian, Schwartzberg, Lee
Publicado 2017

Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy

por Chasen, Martin, Urban, Laszlo, Schnadig, Ian, Rapoport, Bernardo, Powers, Dan, Arora, Sujata, Navari, Rudolph, Schwartzberg, Lee, Gridelli, Cesare
Publicado 2016

Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy

por Hesketh, Paul J., Schnadig, Ian D., Schwartzberg, Lee S., Modiano, Manuel R., Jordan, Karin, Arora, Sujata, Powers, Dan, Aapro, Matti
Publicado 2016

APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophospha...

por Schnadig, Ian D, Agajanian, Richy, Dakhil, Christopher, Gabrail, Nashat, Vacirca, Jeffrey, Taylor, Charles, Wilks, Sharon, Braun, Eduardo, Mosier, Michael C, Geller, Robert B, Schwartzberg, Lee, Vogelzang, Nicholas
Publicado 2017

Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer

por Sweeney, Christopher J., Percent, Ivor J., Babu, Sunil, Cultrera, Jennifer L., Mehlhaff, Bryan A., Goodman, Oscar B., Morris, David S., Schnadig, Ian D., Albany, Costantine, Shore, Neal D., Sieber, Paul R., Guba, Susan C., Zhang, Wei, Wacheck, Volker, Donoho, Gregory P., Szpurka, Anna M., Callies, Sophie, Lin, Boris Kin, Bendell, Johanna C.
Publicado 2022